

Supplemental prophylactic intervention for chemotherapy-induced nausea and emesis (spice) trial: Protocol for a multi-centre double-blind placebo-controlled randomized trial

Crichton, Megan; Marx, Wolfgang; McCarthy, Alexandra; Marshall, Skye; Molassiotis, Alex; Ried, Karin; Bird, Robert; Lohning, Anna Elizabeth; Isenring, Elisabeth

Published in:
Supportive Care in Cancer

DOI:
[10.1007/s00520-018-4193-2](https://doi.org/10.1007/s00520-018-4193-2)

Licence:
CC BY-NC-ND

[Link to output in Bond University research repository.](#)

Recommended citation(APA):
Crichton, M., Marx, W., McCarthy, A., Marshall, S., Molassiotis, A., Ried, K., Bird, R., Lohning, A. E., & Isenring, E. (2018). Supplemental prophylactic intervention for chemotherapy-induced nausea and emesis (spice) trial: Protocol for a multi-centre double-blind placebo-controlled randomized trial. *Supportive Care in Cancer*, 26(S2), S169. [eP245]. <https://doi.org/10.1007/s00520-018-4193-2>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository coordinator.

Ginger for chemotherapy-induced nausea and vomiting?

 Dr Wolfgang Marx
Research Fellow
Deakin University

 Prof. Sandie McCarthy
Head of School of Nursing
University of Auckland

 Dr Skye Marshall
Research Fellow
Bond University

 Megan Crichton
PhD Scholar
Bond University

 Prof. Alex Molassiotis
Head of School of Nursing
Hong Kong Polytech University

 A Prof. Karin Ried
???
 Dr Robert Bird
Head of Haematol.
Princess Alexandra Hospital

 A Prof. Anna Lohning
???
 Prof. Liz Isenring
Head of Nutr & Dietetics
Bond University


Introduction

Ginger may have the potential to act as an adjuvant therapy for chemotherapy-induced nausea and vomiting (CINV). Despite advances in anti-cancer treatments and anti-emetic medication, low risk and cost-effective therapies to improve nausea-related QoL, symptom management and ultimately the survival of patients undergoing chemotherapy are needed.

Research aim: To assess the efficacy (reduced incidence and severity of CINV, enhanced quality of life), safety, cost-effectiveness, and impact on gut microbiota of a standardized adjuvant ginger root supplement.

Intervention

- **Study Design:** Multi-centre double-blind placebo-controlled randomized trial.
- **Recruitment:** Two hospitals in Brisbane, Queensland, Australia up until April 2019. Target sample size: N=300.
- **Supplementation Schedule:** 4x 300mg over-encapsulated capsules of ginger per day (1.2g ginger/60mg gingerols per day) OR 4x 300mg over-encapsulated capsules of placebo per day (1.2g inner filler microcrystalline cellulose) → 1x capsule every 3-4 hours → capsules consumed for 5 days → commencing Day 1 of CTx Cycle 1 → For Cycles 1 to 3.
- **Alterations to Standard Care:** No changes to standard care. Use of anti-emetic medications prescribed by medical teams permitted during the trial.

Eligibility Criteria

INCLUDED

- Chemotherapy-naïve
- Moderately to highly emetogenic CTX
- Single-day CTX regimen
- Age >18 years
- English speaking
- Adequate physical function
- Ability to safely swallow capsules
- Cognitive ability to understand study purpose and adhere to study

EXCLUDED

- Concurrent radiotherapy
- Concurrent use of ginger in food/supplement/drinks
- History of adverse event to ginger
- Prescribed anti-coagulants, NSAIDs or hypoglycaemics
- Self-prescribed nausea therapies
- Chronic alcohol use (>14 standard drinks per week)
- Experiencing nausea and/or vomiting for reasons other than CTX
- Gall stones or liver disease
- Thrombocytopenia
- Pregnant or lactating women

Study Procedure

Timepoint	T0	T1	T2	T3	T4
	Pre- CTX	Day before CTX	Day of CTX	4-days post-CTX	5-8 days post-CTX
CTX cycle (C)	1 only	1 - 3	1 - 3	1 - 3	1 - 3
Screened and consented	✓				
Participant characteristics	✓				
Delivery of supplements	✓				
Delivery of Participant Booklet	✓				
Nutrition status (Scored PG-SGA)	✓		✓ (C2-3)		
Supplements consumed			✓	✓	
CIN-related QoL (FLIE-5DR)		✓		✓	
Global QoL (EQ-5D-5L)		✓		✓	
Anticipatory nausea and vomiting		✓			
Nausea and vomiting (MAT)			✓	✓	
Depression and anxiety (HADS)			✓		
Fatigue (FACIT-F)			✓		✓
Health service use				✓ (C3)	
Blinding and adherence					✓
Concurrent ginger intake	✓	✓	✓	✓	✓
Adverse events					✓
Stool swab sample	✓				✓

Results

- N=38 recruited from Site A since commencing October 2017. Recruitment expected to commence at Site B July 2018.
- 85% response rate.

- 55% female; mean age 59 ± 12 years; 36% lung cancer, 21% breast, 12% lymphoma, 24% other.
- No reported serious adverse events relatable to the study intervention.

Outcomes

This study, aimed to be completed in April 2019, will:

- ✓ evaluate the safety of ginger supplementation;
- ✓ examine the ginger formulation and dosing regimen needed;
- ✓ control potential confounders;
- ✓ indicate the capacity of ginger to ameliorate CINV-related effects such as fatigue and compromised nutrition.